What Can You Tell Me About Gout

What Can You Tell Me About Gout 10 out of 10 based on 68 ratings.
 

Annals of the Rheumatic Diseases ARD is an international peer review journal and one of more than What Can You Tell Me About Gout 40 specialist titles published by BMJ Group. What Can You Tell Me About Gout it is co-owned with the European League Against Rheumatism EULAR. Patients who are at risk of having a condition known as G6 PD deficiency should be screened by their physician prior to starting therapy with KRYSTEXXA.

MVP”. Duke developed the recombinant uricase enzyme and MVP developed the PEG ylation technology used in the manufacture of KRYSTEXXA. These risks trends and uncertainties are in some instances beyond our control.

Symptoms of gout may include painful flares pain or swelling in the joints known as “gouty arthritis” or deposits of uric acid crystals under the skin called “tophi.” Although most cases of gout can be controlled with conventional urate-lowering therapy when uric acid levels remain high and symptoms persist despite treatment efforts chronic gout may be defined as refractory. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University “Duke” and Mountain View Pharmaceuticals Inc. “MVP”. Duke developed the recombinant uricase enzyme and MVP developed the PEG ylation technology used in the manufacture of KRYSTEXXA.

We may not actually achieve the plans intentions or expectations disclosed in our forward-looking statements and What Can You Tell Me About Gout What Can You Tell Me About Gout you should not place undue reliance on our forward-looking statements which speak only as of the date of publication of this press release. Actual results or events could differ materially from the plans intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions mergers dispositions joint ventures or investments that we may make.

Discontinue oral urate-lowering therapies before instituting KRYSTEXXA and do not institute oral urate-lowering therapy while the patient is on KRYSTEXXA therapy. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure and monitor patients closely following infusion. Patients receiving re-treatment may be at increased risk for anaphylaxis and infusion reactions and should be monitored carefully.

Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information current expectations assumptions estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Other important factors that may affect our business are set forth more fully in our reports filed with the Securities and Exchange Commission

What Can You Tell Me About Gout

to which investors are referred for further information. We may not actually achieve the plans intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements which speak only as of the date of publication of this press release. Actual results or events could differ materially from the What Can You Tell Me About Gout plans intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions mergers dispositions joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and except as required by law assume no obligation to update any forward-looking statements.

These risks trends and uncertainties are in some instances beyond our control. Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying

words. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information current expectations assumptions estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate

  • We do not have a policy of updating or revising forward-looking statements and except as required by law assume no obligation to update any forward-looking statements
  • Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying words
  • These risks trends and uncertainties are in some instances beyond our control
  • Symptoms of gout are caused by the body’s response to the presence of uric acid crystals in the joints and surrounding tissue which form when uric acid levels in the blood are elevated a condition called hyperuricemia
  • Patients receiving re-treatment may be at increased risk for anaphylaxis and infusion reactions and should be monitored carefully
  • In most patients defined as KRYSTEXXA responders in the Phase III trials plasma and serum uric acid levels remained less than 6 mg/dL and sustained and progressive improvements in tophus resolution and flare incidence were seen throughout the study period

. Other important factors

that may affect our business are set forth more fully in our reports filed with the Securities and Exchange Commission to which investors are referred for further information.

These risks trends and uncertainties are in some instances beyond our control. Words such as “anticipate” “believe” “estimate” “expect” “intend” “plan” “will” and other similar expressions identify forward-looking statements although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information current expectations assumptions estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Other important factors that may affect our business are set forth more fully in our reports filed with the Securities and Exchange Commission to which investors are referred for further information.

Patients received either 8 mg KRYSTEXXA every two weeks or the same dose every four weeks for the management of RCG. Consistent with Phase III trials gout flares and injection reactions were the most frequently reported adverse events 71 percent and 44 percent of patients respectively and they were least common in patients with a sustained response to KRYSTEXXA and those receiving treatment every two weeks. In most patients defined as KRYSTEXXA responders in the Phase III trials plasma and serum uric acid levels remained What Can You Tell Me About Gout less than 6 mg/dL and sustained and progressive improvements in tophus resolution and flare incidence were seen throughout the study period.

Tags: , , <BR/>

Leave a Reply

You must be logged in to post a comment.